Home Biosimilar Antibodies Apoptosis CD markers Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262)
For research use only. Not for use in humans.

Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Synonyms: CS-1008

Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). It induces cell apoptosis of cancer cells and inhibits tumor growth and can be used for the research of cancer. MW :150 KD.

Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A260401 Purity: 99% Protein concentration: 12.43mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). It induces cell apoptosis of cancer cells and inhibits tumor growth and can be used for the research of cancer. MW :150 KD.
References

Product Details

CAS No. 918127-53-4
Molecular Weight 150
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06251544 NOT_YET_RECRUITING Breast Cancer; Tumor, Breast; Breast Tumor; Malignant Neoplasm of Breast; Mammary Cancer; Mammary Neoplasm; Mammary Neoplasms, Human; Neoplasm, Breast Baylor College of Medicine 2026-06 PHASE1
NCT02991196 TERMINATED Drug: DS-8273a + nivolumab Colorectal Neoplasm Daiichi Sankyo 2016-12-01 PHASE1
NCT01307891 COMPLETED Drug: Abraxane alone|Drug: Abraxane + Tigatuzumab Breast Cancer; Triple Negative Breast Cancer; Stage IV Breast Cancer; Metastatic Breast Cancer University of Alabama at Birmingham 2011-03 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.